ANNOVIS BIO (ANVS:NYSE)
$1.95 -0.06 (-2.9851%)
Analysed ANNOVIS BIO (ANVS:NYSE) News Sources
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02-04-2026
yahoo.com
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
09-04-2026
yahoo.com
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
10-04-2026
yahoo.com
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
28-04-2026
yahoo.com
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
07-05-2026
yahoo.com
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
15-05-2026
yahoo.com
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
19-05-2026
yahoo.com
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
20-05-2026
yahoo.com
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
22-05-2026
yahoo.com
Annovis Bio Regains NYSE Listing Compliance
26-05-2026
yahoo.com
What is the current price of ANNOVIS BIO (ANVS:NYSE)?
The current price of ANNOVIS BIO (ANVS:NYSE) is $1.95.
ANNOVIS BIO (ANVS:NYSE) absolute price change since previous trading day?
The absolute price change of ANNOVIS BIO (ANVS:NYSE) since the previous trading day is $-0.06.
ANNOVIS BIO (ANVS:NYSE) percentage price change since previous trading day?
The percentage price change of ANNOVIS BIO (ANVS:NYSE) since the previous trading day is -2.9851%.
What is the most recent average sentiment score for ANNOVIS BIO (ANVS:NYSE)?
The most recent average sentiment score for ANNOVIS BIO (ANVS:NYSE) is 68 out of 100.
What is the most recent average sentiment for ANNOVIS BIO (ANVS:NYSE)?
The most recent sentiment for ANNOVIS BIO (ANVS:NYSE) is .
SEC-8K** Filing Available For ANNOVIS BIO (ANVS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.